Le Lézard
Classified in: Health
Subjects: NPT, PER

ZERO Appoints Three Prostate Cancer Champions to Board of Directors


WASHINGTON, Oct. 17, 2017 /PRNewswire-USNewswire/ -- Bolstering its commitment to saving lives and empowering a rapidly growing base of advocacy champions, ZERO ? The End of Prostate Cancer added three new members to its Board of Directors this week.

ZERO - The End of Prostate Cancer logo. (PRNewsFoto/ZERO - The End of Prostate Cancer)

Chicago financial executive Ed Lomasney, prostate cancer survivor and member of the Prostate Cancer Research Program Peer Review Panel Tom Hulsey, and Cheryl Nitituk, a 10-year veteran prostate cancer advocate and fundraiser, join a talented board of directors with diverse talents and experience.

"Ed, Tom, and Cheryl are shining examples of ZERO champions ? individuals committed to go to any lengths to help end prostate cancer," Jamie Bearse, ZERO's CEO, said. "They inspire their communities and everyone they meet to strive toward saving lives from this terrible disease and we're thrilled to have them join our Board of Directors."

Ed Lomasney is the Executive Director for Client Service at Cullen Funds in Chicago. When his father was diagnosed with Stage IV prostate cancer, Ed decided to get involved in fighting for a cure. With two young sons and a daughter on the way, Ed is dedicated to fighting for Generation ZERO and to ending prostate cancer as a ZERO Champion. Previously, he served as a Managing Director with John Hancock's Private Client Group and a Vice President at Nuveen Investments.

Tom Hulsey is prostate cancer survivor, endurance athlete, and champion for ZERO. As a member of Team ZERO, Tom represented ZERO at several high-profile events including the IRONMAN World Championship in Kona in 2016 and raised significant funds to help end the disease. Tom is a technology and cyber security professional, as well as a thought leader in cancer survivorship, and a volunteers at the Baylor, Scott & White Cancer Health & Wellness Center. Diagnosed on his 61st birthday, he also mentors new Team ZERO athletes and is a Social Media Ambassador. In 2017 he was named a peer reviewer for the Prostate Cancer Research Program at the Congressionally Directed Medical Research Programs in the Department of Defense. He's also authoring a book on his prostate cancer journey, a beacon of hope and inspiration for cancer survivors.

Cheryl is a veteran ZERO champion and advocate. A former teacher and Advisory Council member at Prince William County Public Schools, Cheryl is a seasoned educator on a mission to educate men and families about prostate cancer. After her husband lost his battle to the disease almost eleven years ago, Cheryl began fundraising for the ZERO Run/Walk ? Capital Area and has since raised more than $89,000, and expanded her efforts to education and awareness as a Social Media Ambassador and Champion. Service to the community has always been of utmost importance to Cheryl.

ZERO's Board of Directors also includes Chairman Quentin "Skip" Lockwood III, Vice Chairman Robert Ginyard, Col. Paul Taylor, Sherry S. Galloway, R.N., L.M.T., Leo Giambarresi, Ph.D., Jim Grohman, Alicia Morgans, M.D., M.P.H., and Jonathan D. Schwartz.

SOURCE ZERO - The End of Prostate Cancer


These press releases may also interest you

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....



News published on and distributed by: